Evolution of Clinical Trial Regulations in Cote D’Ivoire

  • Paule Mireille ALLOUKOU-BOKA Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
  • Anne-Cinthia AMONKOU-N’GUESSAN Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, 01 BPV 34 Abidjan, Côte d’Ivoire
  • Akadjé Richard ALLOUKOU National Institute of Public Health, Abidjan, Côte d’Ivoire
  • Marie France NANGUY Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, 01 BPV 34 Abidjan, Côte d’Ivoire
  • Aziz Flores KAMELAN Félix Houphouët-Boigny University & Angré University Hospital Center, Abidjan, Côte d’Ivoire.
  • Franck Habib GAUZE Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, 01 BPV 34 Abidjan, Côte d’Ivoire
  • Antoine Serge AMARI Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, 01 BPV 34 Abidjan, Côte d’Ivoire
DOI https://doi.org/10.22270/ijdra.v13i4.829

Abstract

Clinical trials are an essential step in bringing innovative medicines to market. Their effective regulation, which protects participants in these trials, is important in West African’s heavy dependence on foreign sources for medicines context, and particularly in Côte d'Ivoire where the government has expressed its desire to develop the local pharmaceutical industry, including innovation. The objective of this study was to describe the regulations governing clinical trials in Côte d’Ivoire. The methodology used consisted in identifying and then analyzing the applicable texts to clinical trials as well as the reports emanating from the bodies involved in the regulation of clinical trials. The results of our study reveal that in Côte d'Ivoire, since 1987, clinical regulation trials, characterized by the creation and organization of the main bodies in charge of managing these trials, has not really evolved. It took about thirty years to observe a major evolution in regulations with the adoption of Presidential Decree No. 2020-407 of April 22, 2020 regulating clinical trials in Côte d’Ivoire. This salutary text incorporates general principles universally accepted in this area such as the protection of persons and their free and informed consent before any testing is conducted. This confirms the role of the Ivorian Pharmaceutical Regulatory Authority in clinical trials monitoring, while still considering National Ethics Committee mandatory opinion. This development in Ivorian regulations is part of a sub-regional project to regulate clinical trials and will become effective with implementing regulations adoption.

Keywords: medicine, clinical trials Regulation, Côte d’Ivoire, Organizations of Medical Sciences (CIOMS), National Ethics Committee

Downloads

Download data is not yet available.

References

1. Bouvenot G, Vray M. Clinical trials - theory, practice and critique. 4th ed. Paris: Lavoisier S; 2006.
2. Bister S. European Union legal framework of the quality and safety of medicinal products and medical devices: implications in French law. Thesis. [Internet]. Toulouse: University of Toulouse; 2017 [cited 2025 Jul 9].p. 1107. Available from: http://www.theses.fr/2017TOU10010
3. Jobert A. Analysis of the role of phase IV studies in assessing drug risk in vulnerable populations. Thesis. Nantes: University of Nantes; 2022. p. 172.
4. French National Agency for Medicines and Health Products Safety (ANSM). BIAL Laboratory Clinical Trial BIA-102474-101: Publication of the Clinical Protocol. Paris: French National Agency for Medicines and Health Products Safety; 2016.
5. Toto N, Douglas E, Gmeiner M and al. Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study. Trials [Internet]. 2020 Jul [cited 2025 Jun 14]; 21 (1): [about 8pp]. Available from:
https://doi.org/10.1186/s13063-020-04620-8
6. Bernard P. Morts sous antibiotiques. Le Monde Afrique [Internet]. Lemonde; 2007 Jul 20 [updated 2009 Jul 30; cited 2025 Jun 22]. Available from:
http://www.lemonde.fr/afrique/article/2007/07/20/nigeria-morts-sous-antibiotique_937701_3212.html
7. Republic of Côte d’Ivoire. Law No. 2015-533 of July 20, 2015 relating to the practice of pharmacy [Internet]. Republic of Côte d’Ivoire; 2015 Jul 20 [cited 2025 Jun 10]. Available from:
https://api.airpdigital.com/storage/documents/Loi%20%20n%C2%B0%202015-533%20du%2020%20juillet%202015%20relative%20a%CC%80%20l'exercice%20de%20la%20pharmacie_0.pdf
8. Republic of Côte d’Ivoire. Ministerial Decree No. 317/SP/DSPH of July 14, 1987, regulating clinical trials of medicinal substances before and after marketing in Côte d’Ivoire; 1987
9. Republic of Côte d’Ivoire. Presidential Decree No. 2001-12 of January 3, 2001, concerning the organization of the Ministry of Public Health; 2001 Jan 03.
10. Coulibaly A, Toumi A. Study for the development of Local Pharmaceutical Industries (LPI) in Côte d'Ivoire. Abidjan: United Nations Industrial Development Organization (UNIDO); 2014.
11. Republic of Côte d’Ivoire. Law No. 2017-541 of August 3, 2017, relating to the regulation of the pharmaceutical sector [Internet]. Republic of Côte d’Ivoire; 2017 Oct 5 [cited 2025 May 2]. Available from:
https://api.airpdigital.com/storage/documents/loi%202017-541%20airp%20jorci.pdf
12. Republic of Côte d’Ivoire. Ministerial Decree No. 871/MSHP of May 17, 2018, concerning the organization and operation of the National Ethics Committee for Life Sciences and Health [Internet]. Republic of Côte d’Ivoire; 2018 May 17 [cited 2025 May 03]. Available from:
https://api.airpdigital.com/storage/documents/arrete%20portant%20organisation%20et%20fonctionneme%20comit%C3%A9%20national%20d'%C3%A9thique%20des%20sciences%20de%20la%20vie%20et%20de%20la%20sant%C3%A9.pdf
13. Mendoza-Caminade A. Medicine and the law: French and European law. Belgium: Larcier; 2017.
14. Republic of Côte d'Ivoire. Presidential Decree No. 2020-407 of April 22, 2020, regulating clinical trials [Internet]. Republic of Côte d’Ivoire; 2020 Jul 06 [cited 2025 Mar 21]. Available from:
https://api.airpdigital.com/storage/documents/De%CC%81cret%20n%C2%B0%202020-407%20du%2022%20avril%202020%20portant%20re%CC%81glementation%20essais%20cliniques.pdf
15. Ivorian Pharmaceutical Regulatory Authority (AIRP). Guidelines on clinical trial applications, authorization applications and substantial amendments. Abidjan: Ivorian Pharmaceutical Regulatory Authority; 2024.
16. European Union. Regulation (EC) No 536/2014 on clinical trials of medicinal products for human use. [Internet]. EU: EC; 2014 May 27 [cited 2025 May 16]. Available from:
https://eur-lex.europa.eu/eli/reg/2014/536/oj/eng
17. Republic of Côte d’Ivoire. Presidential Decree No. 2018-926 of December 12, 2018, concerning the organization and operation of the Ivorian Pharmaceutical Regulatory Authority [Internet]. Republic of Côte d’Ivoire; 2019 Mar 14 [cited 2025 Jun 16]. Available from:
https://api.airpdigital.com/storage/documents/DECRET%202018-926%20DU%2012%20DECEMBRE%202018.pdf
18. Goussard C. Ethics in clinical trials - Foundational principles, international guidelines, roles and responsibilities of ethics committees. médecine/sciences [Internet]. 2007 Aug [cited 2024 Jun 15]; 23(8-9): [about 5pp.]. Available from:
https://ipubli.inserm.fr/bitstream/handle/10608/6243/MS_2007_8-9_777.pdf?sequence=1&isAllowed=y
19. West African Economic and Monetary Union (WAEMU). Regulation No. 02/2005/CM/WAEMU of July 4, 2005, concerning the harmonization of pharmaceutical regulations in the WAEMU Member States; 2005 Jul 04.
20. West African Economic and Monetary Union (WAEMU). Directive No. 06/2020/CM/WAEMU of 28 September 2020 concerning the status of the Pharmaceutical Regulatory Authorities of the WAEMU Member States; 2020 Sep 28.
21. West African Economic and Monetary Union (WAEMU). Regulation No. 01/2022/CM/WAEMU of June 24, 2022, concerning the harmonization of pharmaceutical regulations in WAEMU Member States [Internet]. Official bulletin No. 113; 2022 [cited 2025 May 16]. Available from:
https://www.uemoa.int/sites/default/files/bibliotheque/bulletin-officiel-ndeg113-de-luemoa-deuxieme-trimestre-2022.pdf
22. European Union. Regulation (EC) No 536/2014 on clinical trials of medicinal products for human use [Internet]. EU: EC;2014 May 27 [cited 2025 May 16]. Available from:
https://eur-lex.europa.eu/eli/reg/2014/536/oj/eng
23. Dieye AM, Gueye I, Sy GY and al. Clinical trials in Dakar: survey on knowledge, attitudes and practices of key actors on the period from 2003 to 2007. Thérapie [Internet]. 2008 Mar-Apr [cited 2024 Jun 14];63(2): [about 8pp]. Available from: https://doi.org/10.2515/therapie:2008007
24. Couderc B, Duguet AM, Cambon-Thomsen A, Rial-Sebbag E. Clinical trial and treatment. What ethics in a health emergency? Exploreur Communauté d’universités et établissements de Toulouse [Internet]. Toulouse; 2020 Apr 01 [cited 2025 August 13]. Available from:
https://exploreur.univ-toulouse.fr/essai-clinique-et-traitement-quelle-ethique-en-cas-durgence-sanitaire
25. Kokora E. Survey evaluating the perception of the Abidjan population towards clinical research. Thesis. Abidjan, Côte d’Ivoire: Félix Houphouët-Boigny University of Abidjan; 2024. p.91.
26. Vicari S. Evaluation of the rate and factors influencing patient acceptance or refusal to participate in a clinical trial in general practice: Survey of the Lorraine population consulting general practitioners. Thesis [Internet]. Nancy, University of Lorraine; 2015. [cited 2025 Jun 16].p.43. Available from:
https://hal.univ-lorraine.fr/hal-01733943
27. French Republic. Penal Code, article 223-8 amended by Ordinance 2016-800 of 16 June 2016 - article 6. [Internet]. 2016 Dec 31 [cited 2025 Jun 12]. Available from:
https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000032723038/
28. European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 [Internet]. EU: EC;2006 Dec 27 [cited 2025 May 16]. Available from:
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32006R1901
Statistics
60 Views | 74 Downloads
How to Cite
1.
ALLOUKOU-BOKA PM, AMONKOU-N’GUESSAN A-C, ALLOUKOU AR, NANGUY MF, KAMELAN AF, GAUZE FH, AMARI AS. Evolution of Clinical Trial Regulations in Cote D’Ivoire. Int J Drug Reg Affairs [Internet]. 2025Dec.17 [cited 2026Jan.31];13(4):72-0. Available from: https://www.ijdra.com/index.php/journal/article/view/829
Issue
Vol 13 No 4 (2025): VOLUME 13, ISSUE 4, 2025
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM